News | January 23, 2014

Three-Year Data Shows Stent Treatment Of Blocked Leg Arteries Lasts, Helps Patients Maintain Improved Quality Of Life

Peripheral artery disease PAD treatments Stents Clinical Trial Study STROLL

January 24, 2014 — Peripheral artery disease (PAD) sufferers maintain improved quality of life, including being able to walk farther, three years after being treated with stents to open their blocked leg arteries, according to STROLL trial results presented at the 26th annual International Symposium on Endovascular Therapy (ISET).
 
Leg arteries remained open in nearly three-quarters of patients who were treated with nickel titanium (nitinol) stents, and they continued to enjoy improved quality of life, according to the study.
 
In the study, self-expanding stents were placed in blockages in the superficial femoral artery of 250 patients. Blockages averaged 7.7 cm, and 23.6 percent of them were completely closed. Three years after treatment, 72.7 percent of arteries remained opened in 209 patients. 3.6 percent of stents had fractured, but all were the least-severe form and caused no problems while continuing to keep arteries open. Blood pressure in the legs remained significantly improved, with almost no change over three years. Further, patients maintained their improved health-related quality of life as measured by several factors, including symptoms and walking distance and speed.
 
STROLL (S.M.A.R.T. Nitinol Self-Expanding Stent in the TReatment of Obstructive SuperficiaL FemoraL Artery Disease) is a multicenter, nonrandomized, single-arm prospective trial studying the safety and efficacy of the S.M.A.R.T. stent. Patients were treated at one of 39 centers.
 
Find out more: www.iset.ge

Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now